Cargando…

Screening over Speech in Unselected Populations for Clinical Trials in AD (PROSPECT-AD): Study Design and Protocol

BACKGROUND: Speech impairments are an early feature of Alzheimer’s disease (AD) and consequently, analysing speech performance is a promising new digital biomarker for AD screening. Future clinical AD trials on disease modifying drugs will require a shift to very early identification of individuals...

Descripción completa

Detalles Bibliográficos
Autores principales:	König, Alexandra, Linz, N., Baykara, E., Tröger, J., Ritchie, C., Saunders, S., Teipel, S., Köhler, S., Sánchez-Benavides, G., Grau-Rivera, O., Gispert, J. D., Palmqvist, S., Tideman, P., Hansson, O.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2023
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9851094/ https://www.ncbi.nlm.nih.gov/pubmed/36946458 http://dx.doi.org/10.14283/jpad.2023.11

Ejemplares similares

Language Impairment in Alzheimer’s Disease—Robust and Explainable Evidence for AD-Related Deterioration of Spontaneous Speech Through Multilingual Machine Learning
por: Lindsay, Hali, et al.
Publicado: (2021)

Predicting Depression Severity from Spontaneous Speech as Prompted by a Virtual Agent
por: König, A., et al.
Publicado: (2023)

Validation of the Remote Automated ki:e Speech Biomarker for Cognition in Mild Cognitive Impairment: Verification and Validation following DiME V3 Framework
por: Tröger, Johannes, et al.
Publicado: (2022)

Measuring neuropsychiatric symptoms in patients with early cognitive decline using speech analysis
por: König, Alexandra, et al.
Publicado: (2021)

Detecting subtle signs of depression with automated speech analysis in a non-clinical sample
por: König, Alexandra, et al.
Publicado: (2022)

Sensory Over-Responsivity as an Added Dimension in ADHD
por: Lane, Shelly J., et al.
Publicado: (2019)

Superior infectivity of the fiber chimeric oncolytic adenoviruses Ad5/35 and Ad5/3 over Ad5-delta-24-RGD in primary glioma cultures
por: Stepanenko, Aleksei A., et al.
Publicado: (2021)

Centiloid cut-off values for optimal agreement between PET and CSF core AD biomarkers
por: Salvadó, Gemma, et al.
Publicado: (2019)

The age-related effect on cognitive performance in cognitively healthy elderly is mainly caused by underlying AD pathology or cerebrovascular lesions: implications for cutoffs regarding cognitive impairment
por: Borland, Emma, et al.
Publicado: (2020)

Effect of adding byproducts of chicken slaughter on the quality of sausage over storage
por: Lima, Juliana L., et al.
Publicado: (2021)

AD OK for 2K AD
Publicado: (1999)

Validation of an Automated Speech Analysis of Cognitive Tasks within a Semiautomated Phone Assessment
por: ter Huurne, Daphne, et al.
Publicado: (2023)

Projet AD
por: Gruber, J
Publicado: (1998)

Projet AD
por: Gruber, J
Publicado: (1998)

The antiproton decelerator: AD
por: Baird, S, et al.
Publicado: (1997)

ad
por: Sefcik, Justine
Publicado: (2020)

How Will Aducanumab Approval Impact AD Research?
por: Weiner, Michael W., et al.
Publicado: (2021)

The Accuracy of Speech and Linguistic Analysis in Early Diagnostics of Neurocognitive Disorders in a Memory Clinic Setting
por: ter Huurne, Daphne, et al.
Publicado: (2023)

Neuropsychiatric symptoms in at-risk groups for AD dementia and their association with worry and AD biomarkers—results from the DELCODE study
por: Sannemann, Lena, et al.
Publicado: (2020)

Remote data collection speech analysis and prediction of the identification of Alzheimer’s disease biomarkers in people at risk for Alzheimer’s disease dementia: the Speech on the Phone Assessment (SPeAk) prospective observational study protocol
por: Gregory, Sarah, et al.
Publicado: (2022)

Predicting AD Conversion: Comparison between Prodromal AD Guidelines and Computer Assisted PredictAD Tool
por: Liu, Yawu, et al.
Publicado: (2013)

Status of the Antiproton Decelerator: AD
por: Maury, S, et al.
Publicado: (1996)

AD on target
Publicado: (1999)

Adding Ajax
por: Powers, Shelley
Publicado: (2007)

ADS targets
por: Samec, Karel
Publicado: (2013)

ADS projects
por: Bourquin, Maurice
Publicado: (2013)

ADS accelerators
por: Seidel, Mike
Publicado: (2013)

Cyclotrons for ADS
por: Mandrillon, P.
Publicado: (2013)

AD project
por: Metzger, C
Publicado: (1997)

AD ERRATUM
Publicado: (2021)

An Added Strength
Publicado: (1900)

The antiproton decelerator: AD
por: Baird, S A, et al.
Publicado: (1997)

AD-4 - Biological Effectiveness of Antiprotons Proposal for an Extension of Experiment AD-4.
por: Holzscheiter, M H, et al.
Publicado: (2005)

Immobilization of Cr(3+), Cd(2+), and Pb(2+) added to calcareous soil amended with composted agro-industrial residues
por: Khedr, Mai, et al.
Publicado: (2023)

Association of β-Amyloid Accumulation With Executive Function in Adults With Unimpaired Cognition
por: Tideman, Pontus, et al.
Publicado: (2022)

Google Advertising Tools: Cashing in with AdSense and AdWords
por: Davis, Harold, et al.
Publicado: (2010)

Beam lifetime in the antiproton decelerator (AD)
por: Grobner, O, et al.
Publicado: (1997)

An added dimension to tumour TRAIL sensitivity
por: Healy, Sandra, et al.
Publicado: (2015)

Baseline Ad5 serostatus does not predict Ad5-HIV vaccine-induced expansion of Ad-specific CD4+ T-cells
por: Hutnick, Natalie A., et al.
Publicado: (2009)

Over-distension of the airways by mechanical ventilation in the elderly: adding insult to injury
por: Pop-Vicas, Aurora, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_cuhclc5r5htujj5mi5nhsk76id